Little Green Pharma Ltd. (AU:LGP)
ASX:LGP
Want to see AU:LGP full AI Analyst Report?
Top Page
Little Green Pharma Ltd.
(Sydney:LGP)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.10
▼(-2.00% Downside)
Action:N/A
Date:05/22/26
The score is primarily constrained by inconsistent profitability and still-negative free cash flow despite improvement, alongside a recent revenue decline. These are partially offset by a conservatively levered balance sheet that provides financial flexibility. Technical indicators are broadly neutral, while valuation is difficult to support due to negative earnings and no dividend yield data.
Positive Factors
Conservative balance sheet
A low debt load relative to equity provides durable financial flexibility: it reduces refinancing risk, preserves capacity to fund capital spending in cultivation and manufacturing, and gives the company time to reach sustained operational breakeven without forced dilution or distress financing.
Negative Factors
Inconsistent profitability
Repeated swings between profit and loss indicate the business has not yet converted revenue scale into reliable operating profitability. Persistent volatility undermines reinvestment planning, complicates long-term budgeting, and raises execution risk if margins remain sensitive to mix or one-off items.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A low debt load relative to equity provides durable financial flexibility: it reduces refinancing risk, preserves capacity to fund capital spending in cultivation and manufacturing, and gives the company time to reach sustained operational breakeven without forced dilution or distress financing.
Read all positive factors
Little Green Pharma Ltd. (LGP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$29.97M
Dividend YieldN/A
Average Volume (3M)234.87K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth15.21%
EPS Growth-141.82%
CountryAU
Employees94
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding305,855,900
10 Day Avg. Volume223,605
30 Day Avg. Volume234,865
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.36
Price to Sales (P/S)0.70
P/FCF Ratio-37.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Little Green Pharma Ltd. Business Overview & Revenue Model
Company Description
Little Green Pharma Ltd engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally. It offers cannabis flower medicines, cannabis extracts, tinctures, and APIs. The company was incorpor...
How the Company Makes Money
LGP makes money primarily by selling medicinal cannabis products into regulated medical markets. Its core revenue model is product-based: it cultivates cannabis (including greenhouse/indoor production where applicable), processes it into medical-g...
Little Green Pharma Ltd. Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
74
Positive
Cash Flow
35
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2023 | Mar 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 42.42M | 36.82M | 19.57M | 14.04M | 7.00M |
| Gross Profit | 11.73M | 25.26M | 11.98M | 4.51M | 5.78M |
| EBITDA | 1.85M | -684.00K | -4.64M | -27.03M | 25.38M |
| Net Income | -1.41M | 3.32M | -9.21M | -24.07M | -4.36M |
Balance Sheet | |||||
| Total Assets | 93.75M | 96.12M | 98.62M | 95.95M | 110.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.42M | 2.38M | 12.40M | 20.09M | 40.27M |
| Total Debt | 4.69M | 4.67M | 11.87M | 15.87M | 1.42M |
| Total Liabilities | 10.72M | 11.11M | 16.39M | 20.47M | 17.10M |
| Stockholders Equity | 83.03M | 85.02M | 82.23M | 75.48M | 93.89M |
Cash Flow | |||||
| Free Cash Flow | -790.00K | -1.15M | -11.87M | -24.83M | -6.21M |
| Operating Cash Flow | 39.00K | -917.00K | -6.94M | -17.17M | -5.15M |
| Investing Cash Flow | -948.00K | -1.14M | -14.03M | -7.66M | -12.73M |
| Financing Cash Flow | 25.00K | -530.00K | 13.03M | 4.73M | 53.87M |
Little Green Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$23.86M | -12.06 | 1.66% | 3.28% | 2.11% | -64.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$29.97M | -21.01 | 10.83% | ― | 15.21% | -141.82% | |
45 Neutral | AU$14.81M | -4.15 | -29.05% | ― | 6.14% | -20.00% |
* Healthcare Sector Average
AU:LGP
Little Green Pharma Ltd.
0.10
>-0.01
-5.00%
CNGGF
Cann Group
0.02
0.01
100.00%
HDRPF
Epsilon Healthcare Limited
―
―
―
AU:IDT
IDT Australia Limited
0.03
-0.06
-65.31%
AU:VIT
Cronos Australia Ltd.
0.04
-0.03
-47.76%
Little Green Pharma Ltd. Corporate Events
Little Green Pharma Shareholders Approve Issue of Consideration Shares
May 22, 2026
Little Green Pharma Ltd. has released the results of its General Meeting of shareholders held on 22 May 2026. The company reported that the sole resolution put to shareholders, an approval to issue consideration shares, was passed on a poll with a...
Little Green Pharma outlines March quarter activities with extensive investor disclaimers
May 12, 2026
Little Green Pharma Ltd. released its March 2026 quarterly activities report and Appendix 4C investor presentation, outlining its recent operational and financial performance. The document is framed as general information for investors, emphasizin...
Little Green Pharma Updates on Cannatrek Deal, TGA Probe and Shareholder Vote
May 10, 2026
Little Green Pharma Ltd, an ASX-listed medicinal cannabis producer, is pursuing growth through the proposed acquisition of Cannatrek Ltd via a scheme of arrangement. The combined group would deepen its presence in Australia’s regulated medic...
Little Green Pharma Updates Court Date and Timetable for Cannatrek Acquisition
Apr 23, 2026
Little Green Pharma Ltd has updated the timetable for its proposed acquisition of Cannatrek Ltd, confirming that the Federal Court of Australia has adjourned the second court hearing to 25 May 2026. The company has set new key dates for shareholde...
Little Green Pharma Shareholders Approve Director Termination Benefits, Delay Key Scheme Vote
Apr 22, 2026
Little Green Pharma Ltd. reported the outcomes of its 22 April 2026 General Meeting, where shareholders voted on several resolutions relating to director termination benefits. Resolutions granting termination benefits to executive directors Angus ...
Little Green Pharma Delays Key Vote on Cannatrek Acquisition Scheme
Apr 21, 2026
Little Green Pharma has postponed shareholder consideration of a key resolution linked to its proposed all-share acquisition of Cannatrek Ltd., pushing the vote on issuing new ordinary and convertible shares from 22 April to 22 May 2026. The delay...
Cannatrek Shareholders Back Little Green Pharma Takeover Scheme
Apr 10, 2026
Little Green Pharma has reported that shareholders of Cannatrek Ltd have overwhelmingly approved the proposed scheme of arrangement for LGP to acquire 100% of Cannatrek’s issued capital. The resolution passed with 96.15% of Cannatrek shareho...
Little Green Pharma Advances Cannatrek Takeover With Supplementary Scheme Booklet Dispatch
Apr 1, 2026
Little Green Pharma has confirmed the dispatch of a supplementary scheme booklet to Cannatrek shareholders, providing additional information on LGP’s proposed acquisition of 100% of Cannatrek via a scheme of arrangement. The materials, avail...
Little Green Pharma issues supplementary booklet as Cannatrek scheme advances
Apr 1, 2026
Little Green Pharma has released a supplementary scheme booklet for its proposed acquisition of Cannatrek, after receiving Federal Court approval to dispatch the document. The booklet updates shareholders on the transaction timetable and provides ...
Little Green Pharma Sets Fully Virtual General Meeting for April 2026
Mar 22, 2026
Little Green Pharma Ltd has called a virtual general meeting of shareholders to be held on 22 April 2026, with participation exclusively via a Zoom webinar. The company will provide electronic access to the notice of meeting and related documents ...
Little Green Pharma Calls Virtual General Meeting for April 2026
Mar 22, 2026
Little Green Pharma Ltd. has called a General Meeting of shareholders to be held virtually via Zoom on Wednesday, 22 April 2026 at 3.30 p.m. AWST, with full access details to be provided through the ASX announcements platform and the company’...
Little Green Pharma Retains WA Production Facility as Sale-Leaseback Deal Collapses
Mar 18, 2026
Little Green Pharma has confirmed that a previously announced contract to sell and lease back its South-West Western Australian production facility has been terminated after the parties failed to reach commercial agreement on certain conditions pr...
Little Green Pharma Sends Scheme Booklet for Cannatrek Acquisition
Mar 4, 2026
Little Green Pharma has confirmed the dispatch of the scheme booklet to shareholders of Cannatrek Ltd. as part of its proposed acquisition of 100% of Cannatrek via a scheme of arrangement. The booklet, available electronically and in hard copy, ou...
Little Green Pharma advances Cannatrek takeover as scheme booklet cleared
Mar 4, 2026
Little Green Pharma has taken a key step toward its proposed acquisition of Cannatrek Ltd., confirming that the scheme booklet for the deal has been registered with ASIC and will be distributed to Cannatrek shareholders. The booklet outlines detai...
Little Green Pharma Director Increases Shareholding via Retention Rights Exercise
Feb 26, 2026
Little Green Pharma has reported a change in the holdings of director Michael David Lynch-Bell following the exercise of vested retention share rights. On 26 February 2026, Lynch-Bell converted 140,000 retention share rights into ordinary shares a...
Little Green Pharma Seeks ASX Quotation for New Share Issue
Feb 26, 2026
Little Green Pharma has applied to the Australian Securities Exchange for quotation of 210,000 new ordinary fully paid shares. The new securities, issued on 26 February 2026, reflect the exercise or conversion of existing options or other converti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.